ecrin-mdr-crcClinical2023IPD Sharing (as of September 2023): Yes Description: Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request. Time frame: Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data. Access Criteria: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement. Additional information available: Study Protocol, Statistical Analysis PlanMetastatic Colorectal CancerColorectal CancerColorectal NeoplasmsBRAF V600E Mutation PositiveMetastatic Colorectal CancerColorectal CancerColorectal NeoplasmsBraf V600e Mutation PositiveInterventionalhttps://newmdr.ecrin.org/Study/1522France7Clinical-biological cohortBRAF mutationECRIN MDRRecruitingfalseA Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal CancerThe study will be conducted in patients with metastatic colorectal cancer (mCRC) harboring a BRAFV600E mutation, to collect clinical data and biological samples to be used for research but also to gather real-world clinical data concerning the treatments and the survival outcomes in patients with this pathology.2023-07-151522NCT05639413